1 Background. Colorectal cancer is a worldwide health problem. Despite growing evidence 2 that members of the gut microbiota can drive tumorigenesis, little is known about what 3 happens to it after treatment for an adenoma or carcinoma. This study tested the hypothesis 4 that treatment for adenoma or carcinoma alters the abundance of bacterial populations 5 associated with disease to those associated with a normal colon. We tested this hypothesis 6 by sequencing the 16S rRNA genes in the feces of 67 individuals before and after treatment 7 for adenoma (N = 22), advanced adenoma (N = 19), and carcinoma (N = 26). 8 34 Not only were there large changes in pre versus post-treatment samples for those with 35 carcinoma, but these changes were towards a more normal microbiota. 36 Keywords 37 microbiota; colorectal cancer; polyps; treatment; risk factor. 38 3
Results. There were small changes to the bacterial community associated with 9 adenoma or advanced adenoma and large changes associated with carcinoma. The 10 communities from patients with carcinomas changed significantly more than those with 11 adenoma following treatment (P-value < 0.001). Although treatment was associated with 12 intrapersonal changes, the change in the abundance of individual OTUs in response 13 to treatment was not consistent within diagnosis groups (P-value > 0.05). Because the 14 distribution of OTUs across patients and diagnosis groups was irregular, we used the 15 Random Forest machine learning algorithm to identify groups of OTUs that could be used 16 to classify pre and post-treatment samples for each of the diagnosis groups. Although 17 the three models could differentiate between the pre and post-treatment samples, there 18 was little overlap between the OTUs that were indicative of each treatment. To determine 19 whether individuals who underwent treatment were more likely to have OTUs associated 20 with normal colons we used a larger cohort that contained individuals with normal colons 21 and those with adenomas, advanced adenomas, and carcinomas. We again built Random 22 Forest models and measured the change in the positive probability of having one of 23 the three diagnoses to assess whether the post-treatment samples received the same 24 classification as the pre-treatment samples. Samples from patients who had carcinomas 25 changed towards a microbial milieu that resembles the normal colon after treatment 26 2 (P-value < 0.05). Finally, we were unable to detect any significant differences in the 27 microbiota of individuals treated with surgery alone and those treated with chemotherapy 28 or chemotherapy and radiation (P-value > 0.05). 29 Conclusions. By better understanding the response of the microbiota to treatment for 30 adenomas and carcinomas, it is likely that biomarkers will eventually be validated that can 31 be used to quantify the risk of recurrence and the likelihood of survival. Although it was 32 difficult to identify significant differences between pre and post-treatment samples from 33 patients with adenoma and advanced adenoma, this was not the case for carcinomas.
Background 39 Colorectal cancer (CRC) is the third most common cause of cancer deaths in the 40 United States [1, 2] . Disease mortality has significantly decreased, predominately due to 41 improvements in screening [2] . Despite these improvements, there are still approximately 42 50,000 CRC-related deaths per year in the United States [1] . Current estimates indicate 43 that 20-30% of those who undergo treatment will experience recurrence and 35% of all 44 patients will die within five years [3] [4] [5] . Identification of methods to assess patients' risk of 45 recurrence is of great importance to reduce mortality and healthcare costs. 46 There is growing evidence that the gut microbiota is involved in the progression of CRC. 47 Mouse-based studies have identified populations of Bacteroides fragilis, Escherichia coli, 48 and Fusobacterium nucleatum that alter disease progression [6] [7] [8] [9] [10] . Furthermore, studies 49 that shift the structure of the microbiota through the use of antibiotics or inoculation of 50 germ free mice with human feces have shown that varying community compositions can 51 result in varied tumor burden [11] [12] [13] . Collectively, these studies support the hypothesis 52 that the microbiota can alter the amount of inflammation in the colon and with it the rate of 53 tumorigenesis [14] . 54 Building upon this evidence, several human studies have identified unique signatures of 55 colonic lesions [15] [16] [17] [18] [19] [20] . One line of research has identified community-level differences 56 between those bacteria that are found on and adjacent to colonic lesions and have 57 supported a role for Bacteroides fragilis, Escherichia coli, and Fusobacterium nucleatum 58 in tumorigenesis [21] [22] [23] . Others have proposed feces-based biomarkers that could be 59 used to diagnose the presence of colonic adenomas and carcinomas [24] [25] [26] . These 60 studies have associated Fusobacterium nucleatum and other oral pathogens with colonic 61 lesions (adenoma, advanced adenoma, and carcinoma). They have also noted that the 62 loss of bacteria generally thought to produce short chain fatty acids, which can suppress 63 4 inflammation, is associated with colonic lesions. This suggests that gut bacteria have a 64 role in tumorigenesis with potential as useful biomarkers for aiding in the early detection of 65 disease [21] [22] [23] [24] [25] [26] . 66 Despite advances in understanding the role between the gut microbiota and colonic 67 tumorigenesis, we still do not understand how treatments including resection, 68 chemotherapy, and/or radiation affect the composition of the gut microbiota. If the 69 microbial community drives tumorigenesis then one would hypothesize that treatment to 70 remove a lesion would affect the microbiota and risk of recurrence. To test this hypothesis, 71 we addressed two related questions: Does treatment affect the colonic microbiota in 72 a predictable manner? If so, does the treatment alter the community to more closely 73 resemble that of individuals with normal colons? 74 We answered these questions by sequencing the V4 region of 16S rRNA genes amplified 75 from fecal samples of individuals with adenoma, advanced adenoma, and carcinomas 76 pre and post-treatment. We used classical community analysis to compare the alpha 77 and beta-diversity of communities pre and post-treatment. Next, we generated Random 78 Forest models to identify bacterial populations that were indicative of treatment for each 79 diagnosis group. Finally, we measured the predictive probabilities to assess whether 80 treatment yielded bacterial communities similar to those individuals with normal colons. 81 We found that treatment alters the composition of the gut microbiota and that, for those 82 with carcinomas, the gut microbiota shifted more towards that of a normal colon after 83 treatment. In the individuals with carcinomas, no difference was found by the type of 84 treatment (surgery alone, surgery with chemotherapy, surgery with chemotherapy and 85 radiation). Understanding how the community responds to these treatments could be a 86 valuable tool for identifying biomarkers to quantify the risk of recurrence and the likelihood 87 of survival.
88

Results
89
Treatment for colonic lesions alters the bacterial community structure Within our 90 67-person cohort we tested whether the microbiota of patients with adenoma (N = 22), 91 advanced adenoma (N = 19), or carcinoma (N = 26) had any broad differences between 92 pre and post-treatment samples [ Table 1 ]. None of the individuals in this study had 93 any recorded antibiotic usage that was not associated with surgical treatment of their 94 respective lesion. The structure of the microbial communities of the pre and post-treatment 95 samples differed, as measured by the θ YC beta diversity metric [ Figure 1A ]. We found that 96 the communities obtained pre and post-treatment among the patients with carcinomas 97 changed significantly more than those patients with adenoma (P-value < 0.001). There 98 were no significant differences in the amount of change observed between the patients 99 with adenoma and advanced adenoma or between the patients with advanced adenoma 100 and carcinoma (P-value > 0.05). Next, we tested whether there was a consistent direction 101 in the change in the community structure between the pre and post-treatment samples 102 for each of the diagnosis groups [ Figure 1B -D]. We only observed a consistent shift in 103 community structure for the patients with carcinoma when using a PERMANOVA test 104 (adenoma P-value = 0.999, advanced adenoma P-value = 0.945, and carcinoma P-value 105 = 0.005). Finally, we measured the number of observed OTUs, Shannon evenness, and 106 Shannon diversity in the pre and post-treatment samples and did not observe a significant 107 change for any of the diagnosis groups (P-value > 0.05) [ Table S1 ].
108
The treatment of lesions are not consistent across diagnosis groups. We used two 109 approaches to identify those bacterial populations that change between the two samples 110 for each diagnosis group. First, we sought to identify individual OTUs that could account 111 for the change in overall community structure. However, using a paired Wilcoxon test 112 we were unable to identify any OTUs that were significantly different in the pre and 113 post-treatment groups (P-value > 0.05). It is likely that high inter-individual variation and 114 6 the irregular distribution of OTUs across individuals limited the statistical power of the test. 115 We attempted to overcome these problems by using Random Forest models to identify 116 collections of OTUs that would allow us to differentiate between pre and post-treatment 117 samples from each of the diagnosis groups. To limit the likelihood that the models would 118 over-fit the data because of the relatively small number of subjects in each group, we 119 restricted our models to only incorporate 10 OTUs. Despite this restriction, the models 120 performed well (adenoma AUC range = 0.69 -0.92, advanced adenoma AUC range = 121 0.80 -1.00, carcinoma AUC range = 0.82 -0.98). Interestingly, the 10 OTUs that were 122 used for each model had little overlap with each other [ Figure 2 ]. Although treatment had 123 an impact on the overall community structure, the effect of treatment was not consistent 124 across patients and diagnosis groups. To test this, we used an expanded cohort of 423 individuals that were diagnosed under 129 the same protocol as having normal colons or colons with adenoma, advanced adenoma, 130 or carcinoma [ Table 2 ]. We then constructed Random Forest models to classify the study 131 samples, with the 3 diagnosis groups (adenoma, advanced adenoma, or carcinoma), or 132 having a normal colon. The models performed well (adenoma AUC range = 0.62 -0.72, 133 advanced adenoma AUC range = 0.68 -0.77, carcinoma AUC range = 0.84 -0.90; Figure   134 S1). The OTUs that were incorporated into the adenoma and advanced adenoma models 135 largely overlapped and those OTUs that were used to classify the carcinoma samples 136 were largely distinct from those of the other two models [ Figure 3A ]. Among the OTUs 137 that were shared across the three models were those populations generally considered 138 beneficial to their host (e.g. Faecalibacterium, Lachnospiraceae, Bacteroides, Dorea, Figure S3 ]. Finally, we applied these three models to the pre and post-treatment samples 145 for each diagnosis group and quantified the change in the positive probability of the model. Our study focused on comparing the microbiota of patients diagnosed with adenoma, 173 advanced adenoma, and carcinoma before and after treatment. For all three groups of 174 patients, we observed changes in their microbiota. Some of these changes, specifically 175 for adenoma, may be due to normal temporal variation, however, those with advanced 176 adenoma and carcinoma clearly had large microbiota changes. After treatment, the 177 microbiota of patients with carcinoma changed significantly more than the other groups. 178 This change resulted in communities that more closely resembled those of patients with 179 a normal colon. This may suggest that treatment for carcinoma is not only successful 180 for removing the carcinoma but also at reducing the associated bacterial communities. 181 Understanding the effect of treatment on the microbiota of those diagnosed with carcinomas 182 may have important implications for reducing disease recurrence. It is intriguing that it 183 may be possible to use microbiome-based biomarkers to not only predict the presence of 184 lesions but to also assess the risk of recurrence due to these changes in the microbiota. 185 Patients diagnosed with adenoma and advanced adenoma, however, did not experience a 186 shift towards a community structure that resembled those with normal colons. This may 187 be due to the fundamental differences between the features of adenomas and advanced 188 adenomas and carcinoma. Specifically, carcinomas may create an inflammatory milieu that 189 would impact the structure of the community and removal of that stimulus would alter said 190 structure. It is possible that the difference between the microbiota of patients with adenoma 191 and advanced adenoma and those with normal colons is subtle. This is supported by the 192 reduced ability of our models to correctly classify patients with adenomas and advanced 193 adenomas relative to those diagnosed with carcinomas [ Figure S1 ]. Given the irregular 194 distribution of microbiota across patients in the different diagnosis groups, it is possible that 195 we lacked the statistical power to adequately characterize the change in the communities 196 following treatment. 197 10 There was a subset of patients (6 of the 26 with carcinomas) who demonstrated an elevated 198 probability of carcinoma after treatment. This may reflect an elevated risk of recurrence. 199 The 23.08% prevalence of increased carcinoma probability from our study is within the 200 expected rate of recurrence (20-30% [3,4]). We hypothesized that these individuals may 201 have had more severe tumors; however, the tumor severity of these 6 individuals (3 with 202 Stage II and 3 with Stage III) was similar to the distribution observed among the other 20 203 patients. We also hypothesized that we may have sampled these patients later than the 204 rest and their communities may have reverted to a carcinoma-associated state; however, 205 there was not a statistically significant difference in the length of time between sample 206 collection among those whose probabilities increased (358 (336 -458) days) or decreased 207 (334 (256 -399) days) (Wilcoxon Test; P-value = 0.56) (all days data displayed as median 208 (IQR)). Finally, it is possible that these patients may not have responded to treatment as 209 well as the other 20 patients diagnosed with carcinoma and so the microbiota may not have 210 been impacted the same way. Again, further studies looking at the role of the microbiota in 211 recurrence are needed to understand the dynamics following treatment. 212 Our final hypothesis was that the specific type of treatment altered the structure of 213 the microbiome. The treatment to remove adenomas and advanced adenomas was 214 either polyp removal or surgical resection whereas it was surgical resection alone or 215 in combination with chemotherapy or with chemotherapy and radiation for individuals 216 with carcinoma. Because chemotherapy and radiation target rapidly growing cells, these 217 treatments would be more likely to cause a turnover of the colonic epithelium driving 218 a more significant change in the structure of the microbiota. Although, we were able 219 to test for an effect across these specific types of treatment, the number of patients in 220 each treatment group was relatively small. Finally, those undergoing surgery would have 221 received antibiotics and this may be a potential confounder. However, our pre-treatment 222 stool samples were obtained before the surgery and the post-treatment samples were 223 obtained long after any effects due to antibiotic administration on the microbiome would be 224 11 expected to occur (344 (266 -408) days). We also found no difference in the community 225 structure of those that received surgery and those that did not as a treatment for adenoma 226 or advanced adenoma.
227
Conclusion
228
This study expands upon existing research that has established a role for the microbiota in 229 tumorigenesis and that demonstrated the utility of microbiome-based biomarkers to predict 230 the presence of colonic lesions. We were surprised by the lack of a consistent signal 231 that was associated with treatment of patients with adenomas or advanced adenomas. 232 The lack of a large effect size may be due to differences in the role of bacteria in the 233 formation of adenomas and carcinomas or it could be due to differences in the behaviors 234 and medications within these classes of patients. One of the most exciting of these future 235 directions is the possibility that markers within the microbiota could be used to potentially 236 evaluate the effect of treatment and predict recurrence for those diagnosed with carcinoma. 237 If such an approach is effective, it might be possible to target the microbiota as part of 238 adjuvant therapy, if the biomarkers identified play a key role in the disease process. Our 239 data provides additional evidence on the importance of the microbiota in tumorigenesis by 240 addressing the recovery of the microbiota after treatment and opens interesting avenues 241 of research into how these changes may affect recurrence. Table 1 ]. Patients were 255 diagnosed by colonoscopic examination and histopathological review of any biopsies taken. 256 Patients were classified as having advanced adenoma if they had an adenoma greater 257 than 1 cm, more than three adenomas of any size, or an adenoma with villous histology. 258 This study was approved by the University of Michigan Institutional Review Board. All study 259 participants provided informed consent and the study itself conformed to the guidelines set 260 out by the Helsinki Declaration.
261
Treatment. For this study treatment refers specifically to the removal of a lesion with 262 or without chemotherapy and radiation. The majority of patients undergoing treatment 263 for adenoma or advanced adenoma were not treated surgically [ Table 1 ] but rather via 264 colonoscopy. All patients diagnosed with carcinomas were treated with at least surgery 265 or a combination of surgery and chemotherapy or surgery, chemotherapy, and radiation. 266 The type of chemotherapy used for patients with CRC included Oxaliplatin, Levicovorin, 267 Folfox, Xeloda, Capecitabine, Avastin, Fluorouracil, and Glucovorin. These were used 268 13 individually or in combination with others depending on the patient [ Table 1 ]. If an individual 269 was treated with radiation they were also always treated with chemotherapy. Radiation the important OTUs were obtained by counting the number of times an OTU was present 320 in the top 10% of MDA for each of the 100 different splits. This was then followed with 321 filtering of this list to variables that were only present in more than 50% of these 100 runs. 322 These corresponding reduced OTU normal versus diagnosis models were then put through 323 the same process mentioned in the previous paragraph and were what was used for the 324 final normal versus diagnosis models. For the pre versus post-treatment models the final 325 optimized mtry was 2 and for the normal versus diagnosis models the final optimized mtry 326 was 2. 327 Each model was then applied to our 67-person cohort [ Table 1 ] based on diagnosis: 328 adenoma (pre-treatment adenoma (adenoma n = 22 and disease free n = 0) versus 329 post-treatment adenoma (adenoma n = 0 and disease free n = 22)), advanced adenoma 330 pre-treatment advanced adenoma (advanced adenoma n = 19 and disease free n = 0 ) 331 versus post-treatment advanced adenoma (advanced adenoma n = 0 and disease free 332 n = 19), and carcinoma (pre-treatment carcinoma (carcinoma n = 26 and disease free n 333 = 0) versus post-treatment carcinoma (carcinoma n = 1 and disease free n = 25)). The 334 application of the pre versus post-treatment models generated the probabilities that the 335 sample was a pre-treatment sample. The application of the normal versus diagnosis 336 models generated the probabilities that the sample was that specific diagnosis (adenoma, 337 advanced adenoma, or carcinoma). 
